GlassScriptPhysician profile
Steven M Manders
NPI 1457329104
$1,715.94
in general payments reported to CMS, 2019-2025
23 companies · $783 in 2025
The $783 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.67 · 2020: $12.43 · 2022: $123 · 2023: $348 · 2024: $436 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,484 · Education: $82.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,484.25 |
| Education | $82.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $191.65 | 2022-2025 | Tremfya |
| Abbvie INC. | $191.35 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $165.28 | 2020-2025 | |
| Pfizer INC. | $124.99 | 2022-2025 | |
| Amgen INC. | $119.62 | 2022-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $115.98 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $108.90 | 2022-2025 | Adbry |
| Arcutis Biotherapeutics, INC. | $95.57 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $91.55 | 2023-2025 | Winlevi |
| Ucb, INC. | $66.61 | 2024-2025 | Bimzelx |
| Organon LLC | $65.43 | 2025 | Hadlima, Vtama |
| Genzyme Corporation | $56.24 | 2023-2025 | |
| Lilly USA, LLC | $50.49 | 2023-2024 | Taltz, Olumiant, Ebglyss |
| Dermavant Sciences, INC. | $46.99 | 2023-2024 | Vtama |
| Incyte Corporation | $39.06 | 2025 | Opzelura |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $37.40 | 2025 | Sofdra |
| Journey Medical Corporation | $28.80 | 2022-2023 | |
| Springworks Therapeutics, INC. | $24.36 | 2025 | Gomekli |
| Galderma Laboratories, L.P. | $23.43 | 2025 | Aklief |
| Krystal Biotech INC | $21.04 | 2024 | Vyjuvek |
| Regeneron Healthcare Solutions, INC. | $19.35 | 2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.18 | 2024 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Manders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.